You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
05/22/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
![]() |
2 | |
05/22/23 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
3 |
05/10/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
74 |
05/10/23 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
12 |
05/02/23 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
134 |
04/13/23 | ARS | Annual report to security holders |
![]() |
124 | |
04/13/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
![]() |
3 | |
04/13/23 | DEF 14A | Definitive proxy statements |
![]() |
41 | |
04/04/23 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
04/04/23 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 |